假尿嘧啶核苷作为肾病和肿瘤生物标志物的研究进展  

Research progress of pseudouridine as a biomarker of kidney disease and cancer

作　　者：陈旭 冯娟(综述) 胡晓波[3] 王昌富(审阅) CHEN Xu;FENG Juan;HU Xiaobo;WANG Changfu(Department of Clinical Laboratory,Jingzhou Hospital,Tongji Medical College,Huazhong University of Science and Technology,Jingzhou 434000,Hubei,China;Shanghai Labway Clinical Laboratory,Shanghai 200030,China;Longhua Hospital,Shanghai University of Traditional Chinese Medicine,Shanghai 200031,China)

机构地区：[1]华中科技大学同济医学院附属荆州医院医学检验部,湖北荆州434000 [2]上海兰卫医学检验所,上海200030 [3]上海中医药大学附属龙华医院,上海200031

出　　处：《检验医学》2019年第9期864-867,共4页Laboratory Medicine

摘　　要：假尿嘧啶核苷(PU)是尿嘧啶核苷异构体,主要由转运RNA(tRNA)代谢产生,机体不再重新利用,直接从尿液中排出。随着对PU认识的深入,其作为肾病、肿瘤等疾病的生物标志物越来越受到关注。文章对PU的代谢特点、检测方法及其在肾病和肿瘤诊治中的临床价值进行了综述,并展望PU等小分子物质在代谢组学研究方面的意义。Pseudouridine(PU)is the isomeride of uracil nucleoside,which is mainly produced by the metabolism of transfer RNA(tRNA).PU can not be reused and is eliminated through urine directly.With further study,PU is getting more and more attention as a biomarker.This review describes the metabolic characteristics and determination methods of PU,evaluates the role of PU in the diagnosis and treatment of kidney diseases and cancers,and looks forward to the significance of PU on metabonomics.

关 键 词：假尿嘧啶核苷 慢性肾脏疾病 肝癌 肺癌 

分 类 号：R392.9[医药卫生—免疫学]